Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib

被引：0
|
作者：
Yu, Helena Alexandra
Kerr, Keith
Rolfo, Christian Diego
Fang, Jian
Finocchiaro, Giovanna
Wong, Kam-Hung
Veillon, Remi
Kato, Terufumi
Yang, James Chih-Hsin
Nadal, Ernest
Raskin, Jo
Le, Xiuning
Karachaliou, Niki
Ellers-Lenz, Barbara
OBrate, Aurora
Stroh, Christopher
Piske, Nadine
Boesler, Carsten
Yang, Jinji
Mazieres, Julien
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Aberdeen, Sch Med, Dept Pathol, Aberdeen, Scotland
[3] Aberdeen Royal Infirm, Aberdeen, Scotland
[4] Mt Sinai Med Syst, Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA
[5] Icahn Sch Med, New York, NY USA
[6] Peking Univ Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[7] IRCCS Humanitas Res Hosp, Milan, Italy
[8] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[9] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[10] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[11] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[12] Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain
[13] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[14] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[15] Merck KGaA, Healthcare Business, Global Clin Dev, Darmstadt, Germany
[16] Merck KGaA, Healthcare Business, Dept Biostat, Darmstadt, Germany
[17] Merck KGaA, Healthcare Business, Global Med Affairs, Darmstadt, Germany
[18] Merck KGaA, Healthcare Business, Compan Diagnost & Biomarker Strategy, Darmstadt, Germany
[19] Merck KGaA, Healthcare Business, Clin Biomarkers & Technol, Darmstadt, Germany
[20] Guangdong Gen Hosp & Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China
[21] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9074
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
    de Garibay, G. Ruiz
    Roch, B.
    Garrido Lopez, P.
    Isla, D.
    Aguado, C.
    Callejo Perez, A.
    Marse Fabregat, R.
    Garcia Campelo, M. R.
    Blasco Cordellat, A.
    Sanchez Torres, J. M.
    Bernabe Caro, R.
    Juan Vidal, O. J.
    Carpeno, J. De Castro
    Franco, F. F.
    Ramos Garcia, I.
    Gomez Rueda, A.
    Conde Gallego, E.
    Ponce Aix, S.
    Paz-Ares, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
  • [32] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
    Cheng, Y.
    Yu, Y.
    Fan, Y.
    Jiang, L.
    Wu, L.
    Hu, J.
    Wang, J.
    Yao, W.
    Han, Z.
    Yao, Y.
    Fang, J.
    Sun, M.
    Wang, Q.
    Pan, Y.
    Wu, R.
    Liu, J.
    Liu, Y.
    Kulkarni, D.
    Huang, X.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
  • [33] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [34] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Lee, C. K.
    Laktionov, K.
    Yang, T. Y.
    Yu, Y.
    Kato, T.
    Jiang, L.
    Chewaskulyong, B.
    Geater, S. Lucien
    Maurel, J. M.
    Rojas, C.
    Havel, L.
    Shepherd, F. A.
    Tanaka, K.
    Ghiorghiu, D.
    Monterroso, E. Armenteros
    Huang, X.
    Yang, J. C. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
  • [35] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Lee, C. K.
    Laktionov, K.
    Yang, T-Y.
    Yu, Y.
    Kato, T.
    Jiang, L.
    Chewaskulyong, B.
    Geater, S. Lucien
    Maurel, J-M.
    Rojas, C.
    Havel, L.
    Shepherd, F. A.
    Tanaka, K.
    Ghiorghiu, D.
    Monterroso, E. Armenteros
    Huang, X.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1668 - S1668
  • [36] Durvalumab plus chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
    Cho, B. C.
    Ahn, M. J.
    Baik, C.
    Garcia, R.
    Goldman, J. W.
    Kim, S-W.
    Lee, J. S.
    Nishio, M.
    Ponce, S.
    Salgia, R.
    Teraoka, S.
    Yoshida, T.
    Yu, H. A.
    Ambrose, H.
    Cosaert, J.
    Hartmaier, R.
    Maidment, J.
    Pluta, M.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2022, 33 : S34 - S35
  • [37] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
    Cronin-Fenton, D.
    Dalvi, T.
    Hedgeman, E.
    Norgaard, M.
    Petersen, L.
    Hansen, H.
    Fryzek, J.
    Lawrence, D.
    Walker, J.
    Mellemgaard, A.
    Rasmussen, T.
    Shire, N.
    Rigas, J.
    Potter, D.
    Hamilton-Dutoit, S.
    Sorensen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
  • [38] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [39] Clinical outcomes of patients with advanced EGFR mutation positive (EGFRm) non-small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib resistance: A multicentre retrospective study
    Chen, O. H.
    Kam, T. Y.
    Du, Q.
    Nyaw, S. F.
    Chik, Y. K.
    Cheung, A. H.
    Chow, C.
    Chan, L. L.
    Yan, K. C. K.
    Mok, K.
    Wong, W.
    Tsui, G.
    Chen, C. C. A.
    Mok, T. S. K.
    Li, S. C. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1663 - S1663
  • [40] Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
    Minari, Roberta
    Bordi, Paola
    La Monica, Silvia
    Squadrilli, Anna
    Leonetti, Alessandro
    Bottarelli, Lorena
    Azzoni, Cinzia
    Lagrasta, Costanza Anna Maria
    Gnetti, Letizia
    Campanini, Nicoletta
    Petronini, Pier Giorgio
    Alfieri, Roberta
    Tiseo, Marcello
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E89 - E91
12345